Genflow Biosciences Plc (LON:GENF, OTCQB: GENFF, FRA:WQ5), a biotechnology company focused on the development of gene therapies for age-related diseases, has announced the expansion of its engagement with participants in the global animal health sector.
Following the positive preliminary interim results reported in an RNS on February 12, 2026 and the initial execution of confidentiality agreements, the Company has entered into additional confidential agreements with Tier-1 global animal health companies in connection with the ongoing review of data from its canine SIRT6 cent gene therapy programme. These agreements, together with previous confidentiality agreements, reflect a broadening base of third-party evaluation of the Company’s data and underlying technology.
These interactions support an ongoing evaluation process and remain exploratory in nature. The Company will provide further updates as appropriate.
Dr Eric Leire, Chief Executive Officer of Genflow Biosciences said: “We are encouraged by continued and new discussions with leading participants in the animal health sector. Our previously reported positive preliminary findings are now being evaluated by a broader group of counterparties under confidentiality agreements as part of an ongoing review of our canine programme. Our focus remains on advancing the programme and generating further data to support future development.”
